Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
30 active Medicare policies list M83.8, and 2 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2018
JK · Effective Apr 1, 2018
2 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M83.8 |
|---|---|---|
| Measurement of Serum 1,25-dihydroxyvitamin D | Not recorded | Covered |
| Policy | Effective | Status of M83.8 |
|---|---|---|
| Crysvita (Burosumab-Twza) | May 1, 2026 | Covered |
JE · Effective Feb 3, 2017
JF · Effective Feb 3, 2017
JJ · Effective Jan 29, 2023
JM · Effective Jan 29, 2023
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
JL · Effective Oct 1, 2025
National · Effective Aug 6, 2026
J5 · Effective Oct 1, 2024
National · Effective Aug 14, 2025
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2023
J9 · Effective Oct 1, 2023